Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1159/000442661 http://scihub22266oqcxt.onion/10.1159/000442661 C4777938!4777938!26955352     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Case+Rep+Ophthalmol 2015 ; 6 (3): 477-81 Nephropedia Template TP {{tp|p=26955352|t=2015. Eplerenone in the Treatment of Polypoidal Choroidal Vasculopathy |pdf=|usr=}}{{26955352}} gab.com Text Eplerenone in the Treatment of Polypoidal Choroidal Vasculopathy JO: Case Rep Ophthalmol http://www.kidney.de/pget.php?&tw=1&pmid=26955352 #FOAvip Overactivation of mineralocorticoid receptor pathways has been implicated in the pathophysiology of central serous chorioretinopathy (CSCR). Recently, mineralocorticoid receptor antagonists such as eplerenone have demonstrated success in treating subretinal fluid in CSCR. This case demonstrates a patient who was initially presumed to have subretinal fluid secondary to CSCR and was started on a trial of oral eplerenone. It quickly became evident that her subretinal fluid was secondary to a peripapillary polypoidal choroidal vasculopathy network, but she demonstrated a significant improvement with oral eplerenone. To the authors' knowledge, this is the first case of eplerenone use to treat polypoidal choroidal vasculopathy. Twit Text FOAVip Eplerenone in the Treatment of Polypoidal Choroidal Vasculopathy ????Case Rep Ophthalmol http://www.kidney.de/pget.php?&tw=1&pmid=26955352 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26955352 #FOAvip English Wikipedia <ref>{{Cite pmid|26955352}}</ref> Eplerenone in the Treatment of Polypoidal Choroidal Vasculopathy #MMPMID26955352 Kapoor KG; Wagner AL Case Rep Ophthalmol 2015[Sep]; 6 (3): 477-81 PMID26955352show ga Overactivation of mineralocorticoid receptor pathways has been implicated in the pathophysiology of central serous chorioretinopathy (CSCR). Recently, mineralocorticoid receptor antagonists such as eplerenone have demonstrated success in treating subretinal fluid in CSCR. This case demonstrates a patient who was initially presumed to have subretinal fluid secondary to CSCR and was started on a trial of oral eplerenone. It quickly became evident that her subretinal fluid was secondary to a peripapillary polypoidal choroidal vasculopathy network, but she demonstrated a significant improvement with oral eplerenone. To the authors' knowledge, this is the first case of eplerenone use to treat polypoidal choroidal vasculopathy. äEplerenone in the Treatment of Polypoidal Choroidal Vasculopathy (epmc).pdf DeepDyve Pubget Overpricing